NASDAQ$IMNM
Immunome Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2024.
Immunome announced its third quarter 2024 financial results, highlighting the advancement of its pipeline with topline data for the RINGSIDE Part B trial of AL102 expected in the second half of 2025, and IND submissions for IM-1021 and IM-3050 on track.
- Full enrollment was completed in February 2024 for the Phase 3 RINGSIDE Part B study of AL102 for desmoid tumors, with topline data expected in the second half of 2025.
- Additional manufacturing and pharmacology work is underway to support a new drug application filing for AL102.
- IND submissions for IM-1021 and IM-3050 are anticipated in the first quarter of 2025.
- The discovery team is focused on discovering ADCs and the differentiated profile of HC74 offers opportunities for portfolio expansion.
Headline financials
Revenue & EPS history
Immunome · Revenue · Quarterly
$2.91M
Forward guidance
Immunome expects to report topline data for the RINGSIDE Part B trial in the second half of 2025 and anticipates submitting INDs for IM-1021 and IM-3050 in the first quarter of 2025.
Tailwinds
- Advancing an innovative portfolio of therapeutics.
- Topline data for the RINGSIDE Part B trial of AL102 is expected in the second half of 2025.
- IND submissions for IM-1021 and IM-3050 are on track for the first quarter of 2025.
- Focus on discovering ADCs that effectively pursue novel targets.
- Differentiated profile of HC74 offers exciting opportunities for portfolio expansion.
Headwinds
- Risk that Immunome will not be able to realize the benefits of its strategic transactions.
- Risk that regulatory approvals for Immunome’s programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions.
- Risk that pre-clinical data may not be predictive of clinical data.
- Risk that Immunome’s product candidates and development candidates fail to achieve their intended endpoints.
- Uncertainties related to Immunome’s capital requirements and Immunome’s expected cash runway.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
+0.8%
Avg return
Earnings day
-2.4%
Avg return
5 days after
+0.6%
Avg return
30 days after
32%
7 / 22 earnings
Positive
+24.1%
Q4 2021
Best reaction
-10.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.3% | -9.1% | -20.0% | |
| Q4 2025 | +4.7% | -1.0% | +1.4% | |
| Q3 2025 | -5.0% | +2.5% | +12.3% | |
| Q1 2025 | +1.1% | -1.0% | +15.0% | |
| Q4 2024 | -4.0% | -18.9% | -7.7% | |
| Q3 2024 | -10.8% | -24.5% | +0.7% | |
| Q2 2024 | +4.7% | +4.7% | +11.9% | |
| Q1 2024 | -1.3% | -6.2% | -3.2% | |
| Q4 2023 | -2.3% | -16.2% | -46.2% | |
| Q3 2023 | -8.1% | -8.9% | -12.2% | |
| Q2 2023 | -1.9% | -0.8% | +3.9% | |
| Q1 2023 | +2.3% | +11.9% | -6.2% | |
| Q4 2022 | +20.8% | +18.9% | +2.3% | |
| Q3 2022 | +0.0% | -27.6% | -8.5% | |
| Q2 2022 | +19.3% | +13.6% | +24.7% | |
| Q1 2022 | -2.6% | +19.6% | +46.5% | |
| Q4 2021 | +24.1% | +20.1% | -26.3% | |
| Q3 2021 | -1.0% | -5.1% | -9.3% | |
| Q2 2021 | -3.2% | -11.9% | +51.2% | |
| Q1 2021 | -10.7% | -3.0% | -2.9% | |
| Q4 2020 | -1.0% | -4.3% | -8.3% | |
| Q3 2020 | -5.5% | -6.4% | -6.1% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro